During the past decade, Arkhangelsk Regional Clinical Oncology Dispensary conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 13 clinical trials were completed, i.e. on average, 72.2% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 9 clinical trials were completed. i.e. 180% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Arkhangelsk Regional Clinical Oncology Dispensary" #1 sponsor was "Hoffmann-La Roche" with 13 trials, followed by "Eli Lilly and Company" with 3 trials sponsored, "Achieve Life Sciences" with 1 trials sponsored, "Agennix" with 1 trials sponsored and "Bavarian Nordic" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Arkhangelsk Regional Clinical Oncology Dispensary" #1 collaborator was "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Frontier Science & Technology Research Foundation, Inc." with 1 trials as a collaborator and "Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Arkhangelsk Regional Clinical Oncology Dispensary" are "Non-Small Cell Lung Cancer" (3 trials), "Breast Cancer" (2 trials), "Non Small Cell Lung Cancer" (2 trials), "Triple Negative Breast Cancer" (2 trials) and "Triple-Negative Breast Cancer" (2 trials). Many other conditions were trialed in "Arkhangelsk Regional Clinical Oncology Dispensary" in a lesser frequency.

Most popular intervention types in "Arkhangelsk Regional Clinical Oncology Dispensary" are "Drug" (22 trials), "Biological" (2 trials), "Other" (1 trials), "Procedure" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (7 trials), "Placebo" (6 trials), "Gemcitabine" (5 trials), "Carboplatin" (4 trials) and "Paclitaxel" (4 trials). Other intervention names were less common.

The vast majority of trials in "Arkhangelsk Regional Clinical Oncology Dispensary" are 21 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Arkhangelsk Regional Clinical Oncology Dispensary". undefined are not yet recruiting, 3 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Arkhangelsk Regional Clinical Oncology Dispensary, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Arkhangelsk Regional Clinical Oncology Dispensary, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

Arkhangelsk Regional Clinical Oncology Dispensary has several departments that took part in Clinical trials: "Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council" - 11 trials, "GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology)" - 7 trials, "MNPE Central City Clinical Hospital of Uzhhorod City Council" - 4 trials, "Cherkasy Oncological Dispensary" - 4 trials